+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Fresenius SE & Co KGaA (FRE) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 71 Pages
  • May 2023
  • GlobalData
  • ID: 4239731
Fresenius SE & Co KGaA (FRE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Fresenius SE & Co KGaA (Fresenius) is a global healthcare group that offers products and services for dialysis, hospitals, and outpatient treatment. It provides various dialysis services through its own clinics and sells products to other dialysis service providers. Its major products and services include machines for hemodialysis, acute dialysis and peritoneal dialysis; solutions for infusion therapy; dialysis care services; liver support therapy services; and provision projects and services for hospitals and other health care facilities. It also operates and manages acute care and post-acute care hospitals in Germany through Helios Kliniken Group. Fresenius conducts operations in Asia-Pacific, Europe, Africa and the Americas. The company is headquartered in Bad Homburg, Hessen, Germany.

Fresenius SE & Co KGaA Key Recent Developments

May 17, 2023: Annual General Meeting: Course set for future Fresenius - Company heading in the right direction
Feb 22, 2023: Fresenius strengthens its management board team - new appointment at Fresenius Kabi - expansion of human resources/legal to include ESG
Feb 21, 2023: Fresenius Medical Care delivers against FY22 expectations, sets strategic focus and accelerates transformation
Dec 01, 2022: Fresenius appoints Dennis Hofmann as Head of Corporate Communications

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Fresenius SE & Co KGaA - Key Facts
  • Fresenius SE & Co KGaA - Key Employees
  • Fresenius SE & Co KGaA - Key Employee Biographies
  • Fresenius SE & Co KGaA - Major Products and Services
  • Fresenius SE & Co KGaA - History
  • Fresenius SE & Co KGaA - Company Statement
  • Fresenius SE & Co KGaA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Fresenius SE & Co KGaA - Business Description
  • Business Segment: Fresenius Helios
  • Overview
  • Performance
  • Key Stats
  • Business Segment: Fresenius Kabi
  • Overview
  • Performance
  • Business Segment: Fresenius Medical Care
  • Overview
  • Performance
  • Business Segment: Fresenius Vamed
  • Overview
  • Performance
  • Key Stats
  • Geographical Segment: Africa
  • Performance
  • Geographical Segment: Asia-Pacific
  • Target Markets
  • Performance
  • Geographical Segment: Europe
  • Target Markets
  • Performance
  • Geographical Segment: Latin America
  • Performance
  • Geographical Segment: North America
  • Performance
  • R&D Overview
  • Fresenius SE & Co KGaA - Corporate Strategy
  • Fresenius SE & Co KGaA - SWOT Analysis
  • SWOT Analysis - Overview
  • Fresenius SE & Co KGaA - Strengths
  • Fresenius SE & Co KGaA - Weaknesses
  • Fresenius SE & Co KGaA - Opportunities
  • Fresenius SE & Co KGaA - Threats
  • Fresenius SE & Co KGaA - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Fresenius SE & Co KGaA, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Fresenius SE & Co KGaA, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • Fresenius SE & Co KGaA, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 17, 2023: Annual General Meeting: Course set for future Fresenius - Company heading in the right direction
  • Feb 22, 2023: Fresenius strengthens its management board team - new appointment at Fresenius Kabi - expansion of human resources/legal to include ESG
  • Feb 21, 2023: Fresenius Medical Care delivers against FY22 expectations, sets strategic focus and accelerates transformation
  • Dec 01, 2022: Fresenius appoints Dennis Hofmann as Head of Corporate Communications
  • Aug 20, 2022: Michael Sen to succeed Stephan Sturm as CEO of Fresenius
  • Aug 02, 2022: Fresenius Medical Care publishes financial results for the second quarter and first half of 2022 in line with preliminary results
  • May 17, 2022: Fresenius successfully places bonds with a volume of 1.3 billion euros
  • May 04, 2022: Fresenius with solid start to 2022 despite macroeconomic challenges
  • Apr 04, 2022: New Research Affirms Increase in Access, Equity of COVID-19 Vaccines Administered in Dialysis Centers
  • Feb 22, 2022: Fresenius delivers a strong finish to the year meeting its improved 2021 guidance - Strategic evaluation shows path to accelerated growth
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Fresenius SE & Co KGaA, Key Facts
  • Fresenius SE & Co KGaA, Key Employees
  • Fresenius SE & Co KGaA, Key Employee Biographies
  • Fresenius SE & Co KGaA, Major Products and Services
  • Fresenius SE & Co KGaA, History
  • Fresenius SE & Co KGaA, Other Locations
  • Fresenius SE & Co KGaA, Subsidiaries
  • Fresenius SE & Co KGaA, Key Competitors
  • Fresenius SE & Co KGaA, Ratios based on current share price
  • Fresenius SE & Co KGaA, Annual Ratios
  • Fresenius SE & Co KGaA, Interim Ratios
  • Fresenius SE & Co KGaA, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Fresenius SE & Co KGaA, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • Fresenius SE & Co KGaA, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Fresenius SE & Co KGaA, Performance Chart (2018 - 2022)
  • Fresenius SE & Co KGaA, Ratio Charts
  • Fresenius SE & Co KGaA, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Fresenius SE & Co KGaA, Medical Equipment, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Behn Meyer Europe GmbH
  • Behn Meyer Europe GmbH
  • Geratherm Medical AG
  • Baxter International Inc
  • DaVita Inc
  • Nipro Corp
  • Geratherm Medical AG
  • Baxter International Inc
  • Nipro Corp
  • DaVita Inc